Assess whether a CMC change is a comparability or a new product (1a5c98)

Situation

A CMC change is sits with 505(b)(2) development lead because an inspector asking for batch records you cannot produce this week hit a labeling team facing a boxed-warning debate. Evidence is inspection-readiness findings at a CMO; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose A CMC change is a comparability / A new product using inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize A CMC change is a comparability now; inspection-readiness findings at a CMO already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep A new product in force until inspection-readiness findings at a CMO is completed after an inspector asking for batch records you cannot produce this week for 505(b)(2) development lead.
• Treat inspection-readiness findings at a CMO as A CMC change is a comparability because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page a CMC change is turns on in inspection-readiness findings at a CMO.

Analysis required

• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMC change is for 505(b)(2) development lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week). The follow-on CMC and Development Pathways action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.